Characteristics | All Patientsa(N = 436) | Patients with Durable Response (N = 51) |
---|---|---|
Median age (range), years | 63 (22–94) | 70 (36–91) |
Sex, n (%) | ||
Men | 250 (57) | 31 (61) |
Women | 186 (43) | 20 (39) |
Disease substage, n (%)b | ||
IIIB | 34 (8) | 10 (20) |
IIIC | 97 (22) | 19 (37) |
IVM1a | 118 (27) | 13 (26) |
IVM1b | 90 (21) | 3 (6) |
IVM1c | 96 (22) | 6 (12) |
Missing | 1 (<1) | 0 (0) |
LDH, n (%)a | ||
≤ ULN | 390 (89) | 47 (92) |
> ULN | 20 (5) | 0 (0) |
Line of therapy, n (%) | ||
First-line | 203 (47) | 33 (65) |
Second or greater | 233 (53) | 18 (35) |
ECOG performance status, n (%)a | ||
0 | 306 (70) | 41 (80) |
1 | 114 (26) | 10 (20) |
Missing | 16 (4) | 0 (0) |
HSV serostatus, n (%)a | ||
Positive | 142 (33) | 34 (67) |
Negative | 253 (58) | 13 (26) |
Unknown/missing | 41 (9) | 4 (8) |
BRAF status, n (%) | ||
Mutation | 69 (16) | 5 (10) |
Wild-type | 68 (16) | 6 (12) |
Unknown/missing | 299 (68) | 40 (78) |
Treatment assignment, n (%) | ||
Talimogene laherparepvecc | 295 (68) | 48 (94) |
GM-CSFd | 141 (32) | 3 (6) |